The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field.
The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field.
复制标题
在资源受限的环境中使用埃博拉疗养血浆来治疗埃博拉病毒疾病：该领域的视角。
DOI：
10.1093/cid/civ680
复制
发表时间：
2016-01-01
期刊：
影响因子：
--
通讯作者：
Lynen L
中科院分区：
文献类型：
--
作者：
van Griensven J;De Weiggheleire A;Delamou A;Smith PG;Edwards T;Vandekerckhove P;Bah EI;Colebunders R;Herve I;Lazaygues C;Haba N;Lynen L
世界卫生组织将恢复期血浆（CP）作为当前埃博拉疫情治疗的临床评价列为优先事项。虽然没有有效性数据，但目前的现场经验支持CP作为埃博拉治疗的安全性、可接受性和可行性。2014年9月，世界卫生组织将恢复期血浆（CP）用于治疗目前主要影响几内亚、塞拉利昂和利比里亚的埃博拉病毒病（EVD）的临床评价列为优先事项。在这些国家中，均启动了非随机比较临床试验。截至2015年7月7日，在几内亚科纳克里进行的Ebola-Tx试验招募了102名患者;未观察到严重不良反应。塞拉利昂的Ebola-CP试验和利比里亚的EVD 001试验纳入的患者很少。尽管尚未获得有效性数据，但目前的现场经验支持CP作为EVD治疗的安全性、可接受性和可行性。需要长期随访以及来自非试验环境的数据和干预可扩展性的证据。来源于疫情内的CP是最容易获得的抗EVD抗体来源。在有效的抗病毒药物或单克隆抗体出现之前，CP值得进一步评估。
Clinical evaluation of convalescent plasma (CP) as Ebola treatment in the current outbreak was prioritized by the World Health Organization. Although no efficacy data are available, current field experience supports the safety, acceptability, and feasibility of CP as Ebola treatment. The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola virus disease (EVD) in the current outbreak, predominantly affecting Guinea, Sierra Leone, and Liberia, was prioritized by the World Health Organization in September 2014. In each of these countries, nonrandomized comparative clinical trials were initiated. The Ebola-Tx trial in Conakry, Guinea, enrolled 102 patients by 7 July 2015; no severe adverse reactions were noted. The Ebola-CP trial in Sierra Leone and the EVD001 trial in Liberia have included few patients. Although no efficacy data are available yet, current field experience supports the safety, acceptability, and feasibility of CP as EVD treatment. Longer-term follow-up as well as data from nontrial settings and evidence on the scalability of the intervention are required. CP sourced from within the outbreak is the most readily available source of anti-EVD antibodies. Until the advent of effective antivirals or monoclonal antibodies, CP merits further evaluation.